Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals announced dosing of the first patient in its global Phase 3 ASPENOVA trial evaluating azenosertib, a first-in-class WEE1 inhibitor, against standard chemotherapy in Cyclin E1-positive platinum-resistant ovarian cancer patients. The trial supports a confirmatory study to complement the ongoing Phase 2 DENALI trial aiming for…